Immunotoxicity in advanced lung cancer: how does this influence future practice?
A 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
The next steps and clinical implications for Wnt signalling for the treatment of melanoma